AperçuGraphiqueActualitésTraderScreen

BioCardia/  US09060U6064  /

IEX
14/11/2024  21:48:28 Chg. -0.35 Volume Bid- Demandez à- Haut Bas
2.09USD -14.34% 1,348
Chiffrre d'affaires: 2,850.64		 -Bid taille: - -Ask la taille: - 2.26 2.02
GlobeNewswire 30/08 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasda...
GlobeNewswire 29/08 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire 21/08 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analys...
GlobeNewswire 13/08 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 07/08 BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
GlobeNewswire 30/07 BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire 25/07 Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of ...
GlobeNewswire 17/07 BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter ...
GlobeNewswire 08/07 CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatm...
GlobeNewswire 07/06 BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to ...
GlobeNewswire 21/05 BioCardia Announces Reverse Stock Split
GlobeNewswire 14/05 BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 09/05 BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
GlobeNewswire 01/05 BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in...
GlobeNewswire 25/04 BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Isch...
GlobeNewswire 27/03 BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
GlobeNewswire 20/03 BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
GlobeNewswire 13/03 BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
GlobeNewswire 12/03 BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart ...
GlobeNewswire 04/03 BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial,...
GlobeNewswire 08/02 BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved ...
GlobeNewswire 03/01 BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Share...
GlobeNewswire 19/12/2023 BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchym...
GlobeNewswire 18/12/2023 BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical ...
GlobeNewswire 29/11/2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemi...